Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
Authors
Keywords
Tamoxifen, Metabolites, Age, Endoxifen, CYP2D6
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 141, Issue 2, Pages 243-248
Publisher
Springer Nature
Online
2013-08-31
DOI
10.1007/s10549-013-2677-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
- (2013) Wendy A. Teft et al. BREAST CANCER RESEARCH AND TREATMENT
- Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts
- (2013) Inna Y. Gong et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients
- (2013) Sara Margolin et al. PHARMACOGENOMICS
- CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer
- (2013) Richard R Love et al. SpringerPlus
- Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer
- (2012) Line L Haugan Moi et al. BMC CANCER
- Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
- (2012) Jennifer Gjerde et al. BREAST CANCER RESEARCH AND TREATMENT
- Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04)
- (2012) Hiroyuki Takei et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
- (2011) G. Viale et al. ANNALS OF ONCOLOGY
- Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
- (2011) Kazuma Kiyotani et al. BREAST CANCER RESEARCH AND TREATMENT
- Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials
- (2011) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
- (2011) L Madlensky et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- SULT1A1,CYP2C19and disease-free survival in early breast cancer patients receiving tamoxifen
- (2011) Ann M Moyer et al. PHARMACOGENOMICS
- Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
- (2010) Jennifer Gjerde et al. BMC CANCER
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
- (2010) Dawn L. Hershman et al. BREAST CANCER RESEARCH AND TREATMENT
- Genotype-guided tamoxifen therapy: time to pause for reflection?
- (2009) Timothy L Lash et al. LANCET ONCOLOGY
- Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor–Positive Breast Cancer
- (2007) Cynthia Owusu et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now